• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases.甲状腺细针抽吸细胞学中的 microRNA 特征应用于“意义不明确的不典型病变”病例。
Thyroid. 2012 Jan;22(1):9-16. doi: 10.1089/thy.2011.0081. Epub 2011 Dec 2.
2
UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.超声与基因表达分类器在不明确意义的甲状腺结节中的应用。
Endocr Pract. 2016 Oct;22(10):1199-1203. doi: 10.4158/EP161231.OR. Epub 2016 Jul 13.
3
MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.微 RNA 表达谱有助于从细针抽吸细胞中区分良性结节和甲状腺乳头状癌。
Eur J Endocrinol. 2012 Sep;167(3):393-400. doi: 10.1530/EJE-12-0400. Epub 2012 Jun 22.
4
BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.甲状腺细针穿刺标本的BRAF突变检测可提高意义未明的甲状腺滤泡性病变恶性肿瘤的预测性。
Acta Cytol. 2011;55(6):570-5. doi: 10.1159/000333274. Epub 2011 Dec 9.
5
Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy.应用细针抽吸活检获得的残余细胞中 micro ribonucleic acid 的扩增来区分甲状腺良性和恶性结节。
J Surg Res. 2013 Apr;180(2):216-21. doi: 10.1016/j.jss.2012.04.051. Epub 2012 May 14.
6
A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.四组 miRNA 可准确地区分细针抽吸的恶性和良性甲状腺不定性病变。
Clin Cancer Res. 2012 Apr 1;18(7):2032-8. doi: 10.1158/1078-0432.CCR-11-2487. Epub 2012 Feb 20.
7
Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples.甲状腺细针抽吸活检样本中候选诊断 microRNAs 的评估。
Thyroid. 2012 Mar;22(3):285-91. doi: 10.1089/thy.2011.0313. Epub 2012 Feb 3.
8
Diagnostic value of the candidate microRNAs in thyroid fine-needle aspiration biopsy (FNAB) samples.甲状腺细针穿刺活检样本中候选 microRNAs 的诊断价值。
Horm Mol Biol Clin Investig. 2020 Mar 13;41(2):hmbci-2019-0027. doi: 10.1515/hmbci-2019-0027.
9
Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.甲状腺细针穿刺细胞学检查中可疑阳性结果的意义:一项机构经验。
Cancer Cytopathol. 2014 Oct;122(10):737-44. doi: 10.1002/cncy.21455. Epub 2014 Aug 13.
10
Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.甲状腺结节的组织学诊断与突变组检测之间的相关性:一项为期两年的机构经验
Thyroid. 2016 Aug;26(8):1068-76. doi: 10.1089/thy.2016.0048. Epub 2016 Jul 12.

引用本文的文献

1
The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer.基因和表观遗传修饰作为甲状腺癌诊断和预后潜在生物标志物的作用。
Front Oncol. 2024 Nov 4;14:1474267. doi: 10.3389/fonc.2024.1474267. eCollection 2024.
2
Investigation of the alterations in miRNA expression levels in thyroid nodules and malignancies.甲状腺结节和恶性肿瘤中 miRNA 表达水平变化的研究。
Updates Surg. 2024 Oct;76(6):2329-2335. doi: 10.1007/s13304-024-01978-1. Epub 2024 Sep 6.
3
Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia.在贝塞斯达Ⅲ类甲状腺结节中有效利用微小RNA、BRAF和超声风险评估,对于具有核异型性特征和其他异型性类型的结节需要采用不同的方法。
Cancers (Basel). 2023 Aug 27;15(17):4287. doi: 10.3390/cancers15174287.
4
New biomarkers: prospect for diagnosis and monitoring of thyroid disease.新生物标志物:甲状腺疾病的诊断和监测前景。
Front Endocrinol (Lausanne). 2023 Jul 21;14:1218320. doi: 10.3389/fendo.2023.1218320. eCollection 2023.
5
Diagnostic Significance of FNAB miRNA Expression in Papillary Thyroid Carcinoma.细针穿刺抽吸活检(FNAB)中微小RNA(miRNA)表达在甲状腺乳头状癌中的诊断意义
Diagnostics (Basel). 2022 Jun 3;12(6):1384. doi: 10.3390/diagnostics12061384.
6
Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation.甲状腺微小乳头状癌超声表现与BRAF V600E突变的相关性
J Oncol. 2022 Mar 21;2022:5916379. doi: 10.1155/2022/5916379. eCollection 2022.
7
Genetic alterations in cfDNA of benign and malignant thyroid nodules based on amplicon-based next-generation sequencing.基于扩增子二代测序技术的良恶性甲状腺结节游离DNA的基因改变
Ann Transl Med. 2020 Oct;8(19):1225. doi: 10.21037/atm-20-4544.
8
The lncRNA XIST regulates the tumorigenicity of renal cell carcinoma cells via the miR-302c/SDC1 axis.长链非编码RNA XIST通过miR-302c/SDC1轴调控肾癌细胞的致瘤性。
Int J Clin Exp Pathol. 2017 Jul 1;10(7):7481-7491. eCollection 2017.
9
Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.血清中 microRNA 谱的改变可作为辅助工具,用于鉴别侵袭性甲状腺癌与非侵袭性甲状腺癌和良性甲状腺结节。
Dis Markers. 2019 Sep 16;2019:3717683. doi: 10.1155/2019/3717683. eCollection 2019.
10
The Role of Molecular Testing for the Indeterminate Thyroid FNA.甲状腺细针穿刺抽吸活检结果不确定时的分子检测作用
Genes (Basel). 2019 Sep 23;10(10):736. doi: 10.3390/genes10100736.

本文引用的文献

1
Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach?甲状腺细针抽吸不明确意义的非典型性的临床转归:是否应首选重复细针抽吸作为初始方法?
Am J Clin Pathol. 2011 May;135(5):770-5. doi: 10.1309/AJCP4P2GCCDNHFMY.
2
Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples.开发基于 microRNA 的分子检测方法,用于检测细针抽吸活检样本中的甲状腺乳头状癌。
Thyroid. 2011 Feb;21(2):111-8. doi: 10.1089/thy.2010.0356.
3
A large multicenter correlation study of thyroid nodule cytopathology and histopathology.一项大型多中心甲状腺结节细胞病理学与组织病理学相关性研究。
Thyroid. 2011 Mar;21(3):243-51. doi: 10.1089/thy.2010.0243. Epub 2010 Dec 29.
4
miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.miR-146b 在具有高危特征的成人甲状腺乳头状癌中高度表达,这些特征包括甲状腺外侵犯和 BRAF(V600E)突变。
Thyroid. 2010 May;20(5):489-94. doi: 10.1089/thy.2009.0027.
5
Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours.在甲状腺乳头癌变异型和滤泡状甲状腺肿瘤的包裹型中差异表达的 microRNA 图谱。
Br J Cancer. 2010 Jan 19;102(2):376-82. doi: 10.1038/sj.bjc.6605493. Epub 2009 Dec 22.
6
The Bethesda System for Reporting Thyroid Cytopathology.《甲状腺细胞病理学报告的贝塞斯达系统》
Thyroid. 2009 Nov;19(11):1159-65. doi: 10.1089/thy.2009.0274.
7
Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications.甲状腺肿瘤中的 microRNAs:分子、诊断和治疗意义。
J Clin Pathol. 2009 Nov;62(11):978-85. doi: 10.1136/jcp.2008.063909. Epub 2009 Jul 21.
8
Fine-needle aspiration biopsy of the thyroid: review of cytopathologic features predictive of malignancy.甲状腺细针穿刺活检:预测恶性肿瘤的细胞病理学特征综述
J Otolaryngol Head Neck Surg. 2009 Jun;38(3):348-54.
9
Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.对失调的微小RNA进行分析有助于鉴别低分化甲状腺癌和乳头状甲状腺癌。
Horm Metab Res. 2009 Jun;41(6):475-81. doi: 10.1055/s-0029-1215593. Epub 2009 Apr 15.
10
MicroRNA expression profiles in thyroid tumors.甲状腺肿瘤中的微小RNA表达谱
Endocr Pathol. 2009 Summer;20(2):85-91. doi: 10.1007/s12022-009-9069-z.

甲状腺细针抽吸细胞学中的 microRNA 特征应用于“意义不明确的不典型病变”病例。

MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases.

机构信息

Department of Pathology, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA.

出版信息

Thyroid. 2012 Jan;22(1):9-16. doi: 10.1089/thy.2011.0081. Epub 2011 Dec 2.

DOI:10.1089/thy.2011.0081
PMID:22136206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3247703/
Abstract

BACKGROUND

MicroRNA (miR) expression signatures are proposed to be able to differentiate thyroid cancer from benign thyroid lesions. We selected eight miRs (miR-146b, -221, -187, -197, -346, -30d, -138, and -302c) to examine the potential use of miRs to supplement diagnostic cytology in cases designated as "atypia of undetermined significance."

METHODS

miR expression was measured in thyroid fine needle aspiration (FNA) specimens by quantitative polymerase chain reaction. Gene expression analyses and linear discriminant analysis (LDA) were performed in a training sample set (n=60) to obtain a classification rule to predict FNA cases as benign or malignant. The predictions were cross-validated by comparing with the corresponding histological diagnoses. A validation sample set (n=68) was further tested with the established four-miR LDA classification rule.

RESULTS

A set of four miRs (miR-146b, -221, -187, and -30d) was identified that could differentiate malignant from benign lesions. A four-miR LDA classification rule was obtained and used to predict FNA cases as benign or malignant. For the training sample set, we obtained a diagnostic accuracy of 93.3%, sensitivity of 93.2%, specificity of 93.8%, positive predictive value (PPV) of 0.98, and negative predictive value (NPV) of 0.83. For the validation sample set, we obtained a diagnostic accuracy of 85.3%, sensitivity of 88.9%, specificity of 78.3%, PPV of 0.89, and NPV of 0.78. For the 30 atypia cases in the validation sample set, we obtained a diagnostic accuracy of 73.3%, sensitivity of 63.6%, specificity of 78.9%, PPV of 0.64, and NPV of 0.79. Based on the miR predictions, we classified the atypia cases predicted as "malignant" into "high risk" and those predicted as "benign" into "low risk" categories. While thyroid carcinomas, particularly papillary thyroid carcinomas (PTCs), were relatively enriched in the high-risk category, this particular miR panel is subject to inaccurate results in follicular neoplasias in atypia cases.

CONCLUSIONS

We demonstrate that miR amplification from FNA samples is feasible and that the particular four miR profile in this study can identify PTCs. However, further refinement is required for application to FNA cytology of "atypia of undetermined significance" cases due to low accuracy in classifying follicular neoplasias.

摘要

背景

微小 RNA(miR)表达谱被认为能够区分甲状腺癌与良性甲状腺病变。我们选择了 8 个 miR(miR-146b、-221、-187、-197、-346、-30d、-138 和-302c)来研究 miR 在被指定为“意义未明的非典型性”的病例中补充诊断细胞学的潜在用途。

方法

通过定量聚合酶链反应测量甲状腺细针抽吸(FNA)标本中的 miR 表达。在训练样本集中进行基因表达分析和线性判别分析(LDA),以获得预测 FNA 病例为良性或恶性的分类规则。通过与相应的组织学诊断进行比较,对预测结果进行交叉验证。使用建立的四 miR LDA 分类规则进一步测试验证样本集(n=68)。

结果

确定了一组四个 miR(miR-146b、-221、-187 和-30d),可区分恶性和良性病变。获得了四 miR LDA 分类规则,并用于预测 FNA 病例的良性或恶性。对于训练样本集,我们获得了 93.3%的诊断准确性、93.2%的敏感性、93.8%的特异性、0.98 的阳性预测值(PPV)和 0.83 的阴性预测值(NPV)。对于验证样本集,我们获得了 85.3%的诊断准确性、88.9%的敏感性、78.3%的特异性、0.89 的 PPV 和 0.78 的 NPV。对于验证样本集中的 30 个非典型病例,我们获得了 73.3%的诊断准确性、63.6%的敏感性、78.9%的特异性、0.64 的 PPV 和 0.79 的 NPV。基于 miR 预测,我们将预测为“恶性”的非典型病例分为“高危”类别,将预测为“良性”的病例分为“低危”类别。虽然甲状腺癌,特别是甲状腺乳头状癌(PTC),在高危类别中相对富集,但该特定 miR 组在非典型病例中的滤泡性肿瘤中存在不准确的结果。

结论

我们证明从 FNA 样本中扩增 miR 是可行的,并且本研究中的特定四 miR 谱可以识别 PTC。然而,由于在分类滤泡性肿瘤方面准确性较低,因此需要进一步改进,以应用于“意义未明的非典型性”病例的 FNA 细胞学。